SOURCE: BioLargo, Inc.

BioLargo, Inc.

November 12, 2014 13:58 ET

BioLargo Issued Patent for Its Platform of Liquid and Hydrogel Iodine Technologies

Expanding Intellectual Property Estate and New Unprecedented Results Drive Innovation at BioLargo

SANTA ANA, CA--(Marketwired - Nov 12, 2014) - BioLargo, Inc. (OTCQB: BLGO) announced today the United States Patent and Trademark Office issued patent 8,846,067 titled "antimicrobial solutions and methods" which covers the use of BioLargo's iodine technology in its platform of liquid and hydrogel solutions. The liquid and gel technologies are foundational to multiple products sold under various brands by BioLargo's subsidiary companies, including Nature's Best Solution, NBS, Odor-No-More, and Deodorall. The new patent also covers the wound gel and wound cleanser products in final stages of development at BioLargo subsidiary Clyra Medical Technologies, Inc., being readied for application for FDA approval and licensure. The patent also covers other liquid and gel products in development for disinfection (such as to control bacteria, fungi, spores and viruses), as well as odor control. Additionally, the patent covers the potential use of the company's hydrogel when combined with boron to provide a barrier/absorption technology for radiation leaks.

Regarding the newly issued patent, BioLargo Chief Science Officer Kenneth R. Code stated, "This is the 5th patent issued in 2014, and once again shows the novelty and usefulness of our iodine technologies. These liquid and gel applications are being sold, evaluated, tested or trialed by various strategic alliance candidates, licensing candidates, and granting authorities across multiple industry segments. We are in discussions now with a number of companies and research colleagues that may use our technology to gain market share through licensure." Dennis Calvert, President and CEO of BioLargo added, "Our liquid and gel systems compete at the highest levels with all other disinfecting products. By comparison, our products are environmentally friendly, gentle, non-toxic, non-staining and simple to use, with no known microbial resistance capability. Our intellectual property estate is expanding rapidly as our third party validations continue to demonstrate new unprecedented results."

About BioLargo, Inc.
BioLargo, Inc. (OTCQB: BLGO) makes life better by delivering technology-based products that help solve some of the world's most important problems that threaten water, food, agriculture, healthcare and energy. More information can be found about the company and its subsidiaries at The subsidiary BioLargo Water, Inc. ( showcases the Advanced Oxidation Systems, including its AOS Filter, winner of the 2014 Technology Star Award by New Technology Magazine- 'The First Word on Innovation in the Oil Patch', and a product in development specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. BioLargo also owns a 50% interest in the Isan System, which was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project. The subsidiary Odor-No-More Inc., features award-winning products serving the pet, equine, and consumer markets, including the Nature's Best Solution® and Deodorall® brands. ( The subsidiary Clyra Medical Technologies, Inc. (, focuses on advanced wound care management and is preparing to make FDA 510(k) applications in 2015.

Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K for the year ended December 31, 2013.

Contact Information

  • Company contact:
    Dennis Calvert
    BioLargo, Inc.
    949-643-9540 x1